Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $65
Portfolio Pulse from richadhand@benzinga.com
Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $78 to $65.
July 28, 2023 | 3:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Bristol-Myers Squibb and lowered the price target from $78 to $65.
The lowering of the price target by Wells Fargo indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Bristol-Myers Squibb's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100